Premium
Lacosamide as treatment of epileptic seizures – cost utility results for Sweden
Author(s) -
Bolin K.,
Berggren F.,
Forsgren L.
Publication year - 2010
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2010.01342.x
Subject(s) - lacosamide , medicine , epilepsy , quality adjusted life year , cost–utility analysis , adjunctive treatment , pediatrics , cost effectiveness , psychiatry , risk analysis (engineering)
Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures – cost utility results for Sweden.
Acta Neurol Scand: 2010: 121: 406–412.
© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard. Objectives – To calculate cost per additional quality‐adjusted life‐year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial‐onset seizures as compared to no adjunctive treatment. Materials and methods – A decision‐tree simulation model was constructed to calculate the number of seizures and health‐care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs. Results – All results were calculated for a 24‐, 18‐, 12‐ and 6‐months follow‐up. The cost per additional QALY was estimated to € 27,641 (24 months). Using a willingness‐to‐pay threshold for a QALY of € 50,000 the net marginal value of using lacosamide was estimated to about € 850,000 per 1000 patients. Conclusions – The estimated cost per QALY gained falls within the range of reported estimates of the willingness‐to‐pay for an additional QALY. The results imply that lacosamide is cost‐effective in the treatment of uncontrolled partial‐onset seizures (1 € ≈ 9.6 SEK).